Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 3/20 | 0.45 |
| ▸ | ATM | Q13315 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23641998 | 0.96 | KMT2A (0.52) | SMN1; SMN2KMT2AMEN1POLBATM | |
| SCHEMBL22019013 | 0.86 | MEN1 (0.57) | SMN1; SMN2KMT2AMEN1POLBKDM4E | |
| SCHEMBL21743274 | 0.85 | SMN1; SMN2 (0.69) | SMN1; SMN2KMT2AMEN1POLBATM | |
| SCHEMBL18747350 | 0.85 | SMN1; SMN2 (0.69) | SMN1; SMN2KMT2AMEN1POLBATM | |
| SCHEMBL23641970 | 0.85 | SMN1; SMN2 (0.69) | SMN1; SMN2KMT2AMEN1POLBATM | |
| SCHEMBL21743267 | 0.81 | SMN1; SMN2 (0.69) | SMN1; SMN2KMT2AMEN1POLBATM | |
| SCHEMBL13145353 | 0.81 | SMN1; SMN2 (0.69) | SMN1; SMN2KMT2AMEN1POLBATM | |
| SCHEMBL21941854 | 0.81 | SMN1; SMN2 (0.69) | SMN1; SMN2KMT2AMEN1POLBATM | |
| SCHEMBL13145355 | 0.79 | SMN1; SMN2 (0.67) | SMN1; SMN2KMT2AMEN1POLBATM | |
| SCHEMBL3966966 | 0.76 | SMN1; SMN2 (0.73) | SMN1; SMN2KMT2AMEN1POLBATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200113901-A1 | METHODS OF USING EHMT2 INHIBITORS | Epizyme, Inc. | 2020-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200113901-A1 | METHODS OF USING EHMT2 INHIBITORS | EHMT2, EHMT1, BHMT | SMN1; SMN2 193/4885KMT2A 18/4885MEN1 1816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.